Previous post Next post

Patent battle in India tests Roche’s grip on rare disease market

An Indian court has cleared the way for low-cost alternatives to Roche’s drug Evrysdi for spinal muscular atrophy. What’s behind the decision and what could it mean for rare disease patients everywhere? On October 9 the Delhi High Court refused to issue Roche an injunction to prevent generic manufacturers from making and selling a low-cost version of one of the company’s top selling drugs. The drug risdiplam, sold by the Swiss pharma giant as Evrysdi, was first approved in the US in 2020 for the treatment of spinal muscular atrophy – a genetic disease that leads to muscle loss and wasting. Babies with the most serious form of the disease often don’t live past their second birthday. What does the Delhi court’s ruling mean for patients in India and beyond? Alpana Sharma, the founder of the patient advocacy group Cure SMA Foundation India, told Swissinfo via email that the court’s “move has the potential to significantly improve access to affordable treatment options for SMA patients ... Full story here Are you the author?
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: ,

Permanent link to this article: https://snbchf.com/2025/10/patent-india-tests-roche-disease-market/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.